Impact Factor
4.31
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.56
2,529 total citations
h5-index
69
h5 depth signal
Cited share
81.5%
327 of 401
Total citations
2,529
Citation footprint
Metric signal
6.37
External metric anchor
Self-citation
1.6%
40 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United Kingdom
2,615
United States
863
Australia
711
Germany
496
Italy
494
Citing Fields of Research
Neurodegenerative Disorders
1,835
Neuromuscular Disorders
1,405
Brain Neurological Disorders
913
Nervous System Disorders
573
Neurosciences
390
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
29,536
Articles tracked across the journal lifetime
Indexed publication set
401
327 cited publications
Last 12 months
146
12.2 publications/month
Open access share
47.9%
70 OA publications in the last year
Leading citing country
United Kingdom
2,615 citing publications
Leading citing field
Neurodegenerative Disorders
1,835 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v28n5, Oct. 1965-
v7n3, July 1944-
Active Coverage
Active Coverage
Active Coverage
Research Focus & Classification
Indexed Subjects
Neuromuscular Disorders
Neurodegenerative Disorders
Brain Neurological Disorders
Vascular Disorders
Issuing & Sponsoring Bodies
Contributor
British Medical Association
Broad Categories
Neurology
Neurosurgery
Psychiatry
Neuromuscular Disorders
Neurodegenerative Disorders
Brain Neurological Disorders
Musculoskeletal Disorders
MeSH Descriptors
Neurology
Neurosurgery
Psychiatry
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
02
DOI 10.1136/jnnp-2026-339655
Open DOI
Functional outcome after ischaemic stroke and intracerebral haemorrhage from two national cohorts
03
DOI 10.1136/jnnp-2026-339842
Open DOI
Beyond a single biomarker: a milestone toward precision medicine in aneurysmal subarachnoid haemorrhage
04
DOI 10.1136/jnnp-2026-339534
Open DOI
Air pollution and the risk of multiple sclerosis relapses in the Paris region, the CONFISEP study
Background: Air pollution has been proposed as a short-term trigger of multiple sclerosis (MS) relapses, but delayed effects remain poorly studied in the era of modern disease-modifying therapies (DMTs). We investigated whether weekly ai...
05
DOI 10.1136/jnnp-2026-339153
Open DOI
PABPN1 pathogenic expansion in the UK Biobank: reframing genetic prevalence of oculopharyngeal muscular dystrophy
Background: Oculopharyngeal muscular dystrophy (OPMD) is a rare, late-onset, mostly autosomal dominant muscular dystrophy caused by a trinucleotide GCN repeat expansion in PABPN1 . OPMD affects approximately 1:100 000 individuals in Euro...
06
DOI 10.1136/jnnp-2026-338800
Open DOI
Stroke recurrence after primary intracerebral haemorrhage: a population-based study of clinical and MRI factors associated with recurrence
Background: Survivors of primary intracerebral haemorrhage (ICH) face competing risks of recurrent ICH and ischaemic stroke. We quantified ischaemic stroke recurrence (ISR) and haemorrhagic stroke recurrence (HSR) and examined associated...
07
DOI 10.1136/jnnp-2026-339197
Open DOI
Comparative effectiveness of inebilizumab versus conventional immunotherapies in AQP4-IgG-positive NMOSD: a prospective cohort study with time-varying treatment effects
Background: To compare relapse and disability outcomes of inebilizumab, azathioprine (AZA), mycophenolate mofetil (MMF) and rituximab (RTX) in maintenance-therapy-naive patients with aquaporin-4 IgG-positive neuromyelitis optica spectrum...
08
DOI 10.1136/jnnp-2026-338694
Open DOI
Age and treatment class modify inflammatory risk after disease-modifying therapy discontinuation in older people with MS
Background The effectiveness of disease-modifying therapies (DMTs) in multiple sclerosis (MS) declines with age, while treatment-related adverse events increase. Although discontinuation is increasingly considered in older patients, fact...
09
DOI 10.1136/jnnp-2026-339497
Open DOI
MRI activity in pre-symptomatic multiple sclerosis: the role of paramagnetic rim lesions beyond the 2024 McDonald diagnostic criteria
Background: The 2024 McDonald criteria allow multiple sclerosis (MS) diagnosis in pre-symptomatic individuals but their association with MRI activity remains uncertain. We assessed whether paramagnetic rim lesions (PRL) predict future MR...
10
DOI 10.1136/jnnp-2026-338732
Open DOI
Whole-body quantitative muscle MRI in myotonic dystrophy type 2: a sensitive tool for pattern recognition, disease stratification and objective assessment of clinical severity
Background Myotonic dystrophy type 2 (DM2) is a frequent yet underdiagnosed muscle disorder. Although muscle MRI is increasingly used in neuromuscular disorders, there is an overt lack of evidence regarding its role in DM2. This study ai...
Bibliographical & Catalog Notes
Online version called also: JNNP online.
Online version formerly called: eJNNP.
Supplements with distinctive titles accompany some vols.
Also issued online.
Issued by the British Medical Association.
new ser., v. 7 (1944)-Will not microfilm; 20040413
Vol. 43, no. 1 (1980)19920821 Notice not published Printed on acid-free paper